SG11201501212QA - Quinazoline derivatives and uses thereof as apoptosis inhibitor - Google Patents

Quinazoline derivatives and uses thereof as apoptosis inhibitor

Info

Publication number
SG11201501212QA
SG11201501212QA SG11201501212QA SG11201501212QA SG11201501212QA SG 11201501212Q A SG11201501212Q A SG 11201501212QA SG 11201501212Q A SG11201501212Q A SG 11201501212QA SG 11201501212Q A SG11201501212Q A SG 11201501212QA SG 11201501212Q A SG11201501212Q A SG 11201501212QA
Authority
SG
Singapore
Prior art keywords
quinazoline derivatives
apoptosis inhibitor
apoptosis
inhibitor
quinazoline
Prior art date
Application number
SG11201501212QA
Inventor
Lei Liu
Xiaochun Xu
Xiaoyu Li
Original Assignee
Linx Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Linx Pharmaceutical Co Ltd filed Critical Linx Pharmaceutical Co Ltd
Publication of SG11201501212QA publication Critical patent/SG11201501212QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201501212QA 2012-03-23 2012-03-23 Quinazoline derivatives and uses thereof as apoptosis inhibitor SG11201501212QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2012/000363 WO2013138951A1 (en) 2012-03-23 2012-03-23 Quinazoline derivate and use thereof as apoptosis inhibitor

Publications (1)

Publication Number Publication Date
SG11201501212QA true SG11201501212QA (en) 2015-05-28

Family

ID=49221771

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201501212QA SG11201501212QA (en) 2012-03-23 2012-03-23 Quinazoline derivatives and uses thereof as apoptosis inhibitor

Country Status (3)

Country Link
EP (1) EP2924037A1 (en)
SG (1) SG11201501212QA (en)
WO (1) WO2013138951A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103739596A (en) * 2013-12-10 2014-04-23 刘磊 Quinazoline derivative used for cardio cerebrovascular diseases
CN105017164A (en) * 2015-08-25 2015-11-04 佛山市赛维斯医药科技有限公司 Tyrosine kinase inhibitor containing novel benzo quinazoline and ortho chlorine structure and application
WO2022099578A1 (en) * 2020-11-13 2022-05-19 兰州大学 Application of quinazoline derivative in preparation of drugs for preventing and/or treating gastrointestinal diseases
CN113403387B (en) * 2021-07-16 2022-09-30 兰州大学 Pgk1 application of target in preparing or screening medicine for treating gastrointestinal tract diseases
CN117430614B (en) * 2023-12-20 2024-03-08 首都医科大学 Isoquinoline derivative and synthetic method and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070253957A1 (en) * 2004-10-07 2007-11-01 Cytovia, Inc. Substituted N-Aryl-1H-Pyrazolo[3,4-B]Quinolin-4-Amines and Analogs as Activators of Caspases and Inducers of Apoptosis
CN1927166A (en) * 2006-09-29 2007-03-14 何岩 Terazosin slowly releasing preparation
CN102532110B (en) * 2010-12-22 2014-12-03 刘磊 Quinazoline derivative and application of serving as cell apoptosis inhibitor

Also Published As

Publication number Publication date
WO2013138951A1 (en) 2013-09-26
EP2924037A1 (en) 2015-09-30

Similar Documents

Publication Publication Date Title
HK1209632A1 (en) Irak inhibitors and uses thereof -1 (irak)
PL2920149T3 (en) 3-aminocycloalkyl compounds as ror-gamma-t inhibitors and uses thereof
IL237849A0 (en) Ret inhibitors and uses of same
HK1199023A1 (en) Substituted benzothienylpyrrolotriazines and uses thereof
HK1200822A1 (en) Substituted dipyridylamines and uses thereof
IL237309A0 (en) Benzocyclooctyne compounds and uses thereof
HK1203493A1 (en) Substituted azabicycles and use thereof
EP2890678A4 (en) Glycosidase inhibitors and uses thereof
HK1209107A1 (en) Aminoquinazoline and pyridopyrimidine derivatives
EP2828258A4 (en) Novelpyridopyrimidine derivatives and use thereof
HK1210777A1 (en) Quinazolinone derivatives as parp inhibitors parp
EP2890679A4 (en) Glycosidase inhibitors and uses thereof
EP2847199A4 (en) Permeable glycosidase inhibitors and uses thereof
EP2935283A4 (en) Glycosidase inhibitors and uses thereof
EP2914604A4 (en) Glycosidase inhibitors and uses thereof
EP2890675A4 (en) Glycosidase inhibitors and uses thereof
EP2890676A4 (en) Glycosidase inhibitors and uses thereof
HK1198833A1 (en) N-acylpeptide derivatives and their uses n-
IL236138A (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
HK1206350A1 (en) 2h-imidazol-4-amine compounds and their use as bace inhibitors 2h--4- bace
HK1203198A1 (en) Substituted phenylimidazopyrazoles and use thereof
HK1201270A1 (en) Tetrazol-5-yl- and triazol-5-yl-aryl compounds and use thereof as herbicides -5---5--
SG11201501212QA (en) Quinazoline derivatives and uses thereof as apoptosis inhibitor
PL2882708T3 (en) New compounds and uses thereof
EP2939668A4 (en) Pdk4 inhibitor and use thereof